Shannon Leslie

Shannon Leslie

Auto-generated profile, based on publicly available information

Shannon Leslie

Department of Psychiatry, University of Colorado, Boulder, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MWMichael E. Ward
Michael E. Ward
RCRobert Chen
Robert Chen
HHHsin-Yi Huang
Hsin-Yi Huang
CLConnor Ludwig
Connor Ludwig
MTMaria Telpoukhovskaia
Maria Telpoukhovskaia
AGAri J. Green
Ari J. Green
Individuals with heterozygous GRN mutations exhibit clinicopathological hallmarks of neuronal ceroid lipofuscinosis.

11 December 2017 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CPConstantinos D. Paspalas
Constantinos D. Paspalas
BCBecky Carlyle
Becky Carlyle
SLShannon Leslie
Shannon Leslie
TPTodd M. Preuss
Todd M. Preuss
JCJohanna L. Crimins
Johanna L. Crimins
AAAmy F.T. Arnsten
Amy F.T. Arnsten
Introduction: An animal model of late‐onset Alzheimer's disease is needed to research what causes degeneration in the absence of dominant genetic insults and why the association cortex is particularly vulnerable to degeneration.Methods: We studied the progression of tau and amyloid cortical pathology in the aging rhesus macaque using immunoelectron microscopy and biochemical assays.Results: Aging macaques exhibited the same qualitative pattern and sequence of tau and amyloid cortical pathology as humans, reaching Braak stage III/IV. Pathology began in the young‐adult entorhinal cortex with protein kinase A‐phosphorylation of tau, progressing to fibrillation with paired helical filaments and mature tangles in oldest animals. Tau pathology in the dorsolateral prefrontal cortex paralleled but lagged behind the entorhinal cortex, not afflicting the primary visual cortex.Discussion: The aging rhesus macaque provides the long‐sought animal model for exploring the etiology of late‐onset Alzheimer's disease and for testing preventive strategies.

23 December 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AAAmy F.T. Arnsten
Amy F.T. Arnsten
DDDibyadeep Datta
Dibyadeep Datta
SLShannon Leslie
Shannon Leslie
SYSheng-Tao Yang
Sheng-Tao Yang
MWMin Wang
Min Wang
ANAngus C. Nairn
Angus C. Nairn
Although mouse models of Alzheimer’s disease (AD) have provided tremendous breakthroughs, the etiology of later onset AD remains unknown. In particular, tau pathology in the association cortex is poorly replicated in mouse models. Aging rhesus monkeys naturally develop cognitive deficits, amyloid plaques, and the same qualitative pattern and sequence of tau pathology as humans, with tangles in the oldest animals. Thus, aging rhesus monkeys can play a key role in AD research. For example, aging monkeys can help reveal how synapses in the prefrontal association cortex are uniquely regulated compared to the primary sensory cortex in ways that render them vulnerable to calcium dysregulation and tau phosphorylation, resulting in the selective localization of tau pathology observed in AD. The ability to assay early tau phosphorylation states and perform high-quality immunoelectron microscopy in monkeys is a great advantage, as one can capture early-stage degeneration as it naturally occurs in situ. Our immunoelectron microscopy studies show that phosphorylated tau can induce an “endosomal traffic jam” that drives amyloid precursor protein cleavage to amyloid-β in endosomes. As amyloid-β increases tau phosphorylation, this creates a vicious cycle where varied precipitating factors all lead to a similar phenotype. These data may help explain why circuits with aggressive tau pathology (e.g., entorhinal cortex) may degenerate prior to producing significant amyloid pathology. Aging monkeys therefore can play an important role in identifying and testing potential therapeutics to protect the association cortex, including preventive therapies that are challenging to test in humans.

6 January 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
Dibyadeep DattaDibyadeep Datta
Dibyadeep Datta
SLShannon N. Leslie
Shannon N. Leslie
Yury MorozovYury Morozov
Yury Morozov
ADAlvaro Duque
Alvaro Duque
PRPasko Rakic
Pasko Rakic
AAAmy F.T. Arnsten
Amy F.T. Arnsten
Background: Cognitive impairment in schizophrenia, aging, and Alzheimer’s disease is associated with spine and synapse loss from the dorsolateral prefrontal cortex (dlPFC) layer III. Complement cascade signaling is critical in driving spine loss and disease pathogenesis. Complement signaling is initiated by C1q, which tags synapses for elimination. C1q is thought to be expressed predominately by microglia, but its expression in primate dlPFC has never been examined. The current study assayed C1q levels in aging primate dlPFC and rat medial PFC (mPFC) and used immunoelectron microscopy (immunoEM), immunoblotting, and co-immunoprecipitation (co-IP) to reveal the precise anatomical distribution and interactions of C1q. Methods: Age-related changes in C1q levels in rhesus macaque dlPFC and rat mPFC were examined using immunoblotting. High-spatial resolution immunoEM was used to interrogate the subcellular localization of C1q in aged macaque layer III dlPFC and aged rat layer III mPFC. co-IP techniques quantified protein-protein interactions for C1q and proteins associated with excitatory and inhibitory synapses in macaque dlPFC. Results: C1q levels were markedly increased in the aged macaque dlPFC. Ultrastructural localization found the expected C1q localization in glia, including those ensheathing synapses, but also revealed extensive localization within neurons. C1q was found near synapses, within terminals and in spines, but was also observed in dendrites, often near abnormal mitochondria. Similar analyses in aging rat mPFC corroborated the findings in rhesus macaques. C1q protein increasingly associated with PSD95 with age in macaque, consistent with its synaptic localization as evidenced by EM. Conclusions: These findings reveal novel, intra-neuronal distribution patterns for C1q in the aging primate cortex, including evidence of C1q in dendrites. They suggest that age-related changes in the dlPFC may increase C1q expression and synaptic tagging for glial phagocytosis, a possible mechanism for age-related degeneration.

1 January 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
SLShannon N. Leslie
Shannon N. Leslie
ANAngus C. Nairn
Angus C. Nairn

19 December 2018
Verified
Dataset
Closed access
ANAngus C. Nairn
Angus C. Nairn
SLShannon Leslie
Shannon Leslie
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by two main pathological hallmarks; amyloid beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau. Although, amyloid beta may play a causative role in AD progression, tau pathology {1} and synaptic loss {2} better correlate with cognitive performance. For this study, the authors focused on tau-P301S (P301S) mice, which overexpress a mutant form of human tau. Working predominantly with 9-month-old mice, the authors found that there is clear tau pathology and synaptic dysfunction but not gross hippocampal degeneration. Total tau levels between transgenic and non-transgenic animals were unchanged at both a lysate and post-synaptic density (PSD) level, but certain epitopes of phosphorylated tau were strongly enriched in P301S. Interestingly, the enrichment of tau phosphoepitopes differed between the PSD and lysate (i.e. phosphorylation of Ser404 was elevated in lysate compared to PSD while phosphorylation of Thr231 was elevated in PSD compared to lysate), suggesting a relationship between aberrant localization and specific phosphorylation events. In order to understand the effects of this aberrant tau aggregation, the authors performed label-free quantitative mass spectrometry (MS) on hippocampal PSDs from P301S and non-transgenic mice. They identified 1257 unique proteins, 76 were significantly increased and 45 significantly decreased in P301S mice at 9 months of age (n=3 P301S, 3 Cntrl). Gene ontology analysis revealed down-regulation of processes related to synaptic structure and activity in contrast to up-regulation of pathways related to translation and biosynthesis. Furthermore, the authors found a significant enrichment of AD-associated proteins among the proteins decreased in P301S PSDs; however, the amyloid precursor protein (APP) was significantly enriched in P301S PSDs, suggesting there may be a relationship between tau pathology and amyloid alterations. As a validation of these results, knockdown of some of the proteins identified in this screen was capable of reducing spine density in a hippocampal cultures. The full quantitative MS data are available through this paper as a useful resource. One of the most significantly altered proteins identified in the MS screen was C1q. Dejanovic et al. found that C1q was enriched in total lysates but was even further enriched in PSDs from P301S mice compared to wild type. Utilizing super resolution microscopy as well as correlative light-electron microscopy (CLEM), the authors were able to show increased co-localization between C1q and post-synaptic membranes in P301S. There was strong positive correlation between C1q levels and AT8, a marker of fibrillated tau, staining. The co-accumulation of tau pathology and C1q appeared to be specific to excitatory synapses as PSD-95 but not gephyrin co-immunoprecipitated with both modified human tau and C1q. However, C1q accumulation in the hippocampus lagged behind AT8 staining, only rising above wild-type animals at 9 months of age whereas AT8 staining was evident by 6 months. The authors next turned to human samples to analyze changes in C1q in relation to AD specifically. They found that C1q levels were elevated in the superior frontal gyrus (SFG) ~1.5-fold in "early-stage" AD and ~2-fold in autopsy confirmed AD. At the synaptic level, C1q was also elevated in both early and confirmed AD. Transcript level data from the fusiform gyrus also showed an increase in the complement cascade in confirmed AD patients. These data support a connection between AD pathology and C1q accumulation that warrants further investigation. Given the hypothesis that C1q triggers microglial engulfment and pruning of synapses {3}, Dejanovic et al. examined the relationship between C1q accumulation and microglial engulfment of synapses in P301S mice. They found that at 6 months of age, where there is little rise in C1q, that there was no change in synaptic density or co-localization of microglial lysosomes and synaptic markers. In contrast, at 9 months of age they found elevated levels of C1q, decreased synaptic density, and an increase in co-localization between synaptic and microglial markers, supporting the hypothesis that C1q may drive microglial elimination of synapses. To test this hypothesis the authors utilized a C1q blocking antibody. In vitro the authors found that this antibody was able to prevent the loss of microglia-proximal dendrites in hippocampal rat cultures expressing P301S tau. Next, the authors compared the effects of the anti-C1q antibody in vivo, using P301S mice. They found that 5 days after injection into the dorsal hippocampus of 9-month-old mice, there was a 50% reduction in co-localization between PSD-95 and microglial lysosomes, suggesting that the anti-C1q injection was able to prevent microglial engulfment of synapses. However, at this time point, in slices, electrophysiological changes were not detected. Overall, this paper provides strong supporting evidence that alterations in tau are capable of driving changes in the synaptic proteome and ultimately synaptic loss. Evidence from this paper supports the hypothesis that C1q elevation in neurodegenerative disease may cause microglial engulfment and elimination of spines. The pathways identified in this paper suggest novel drug targets not only for AD but also for tauopathies in general.